Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amylin
Biotech
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
The highest dose of Lilly's amylin-Zepbound combo yielded average weight loss of 54.1-pounds at 48 weeks, with A1C-lowering benefits shown, too.
Marissa Russo
Sep 30, 2026 1:52pm
ADA: Roche, Zealand make tolerability case for petrelintide
Jun 7, 2026 3:00am
AbbVie ties $350M bet to almost 10% weight loss after 12 weeks
Mar 9, 2026 9:50am
Alveus emerges to tackle obesity drug pitfalls with $160M
Jan 8, 2026 7:30am
How Zealand CSO aims to create a 'generational biotech leader'
Dec 12, 2025 1:00pm
Novo pushes ahead with amylin after seeing ph. 3 tolerability
Sep 16, 2025 8:12am
